We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current ONC market cap is 17.05M. The company's latest EPS is GBP -0.0830 and P/E is -2.89.
| Year End 31 August 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 171k | 509k | 3.72M | 3.79M | 1.47M |
| Operating Income | -8.59M | -9.85M | -5.18M | -10.01M | -3.92M |
| Net Income | -8.01M | -8.46M | -4.99M | -11.39M | -6.15M |
| Year End 31 August 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 9.43M | 10.32M | 19.36M | 10.16M | 8.44M |
| Total Liabilities | 1.57M | 10.51M | 14.13M | 14.34M | 7.78M |
| Total Equity | 7.87M | -194k | 5.23M | -4.18M | 657k |
| Year End 31 August 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -7.36M | -8.9M | -4.53M | -6.87M | -6.79M |
| Investing | -163k | 347k | -856k | -931k | 11.58M |
| Financing | -70k | 7.46M | 9.78M | 652k | -3.02M |
| Market Cap | 17.05M |
| Price to Earnings Ratio | -2.89 |
| Price to Sales Ratio | 12.12 |
| Price to Cash Ratio | 5.54 |
| Price to Book Ratio | 27.08 |
| Dividend Yield | - |
| Shares Outstanding | 74.14M |
| Average Volume (1 week) | 80.23k |
| Average Volume (1 Month) | 81.86k |
| 52 Week Change | -43.21% |
| 52 Week High | 44.00 |
| 52 Week Low | 13.00 |
| Spread (Intraday) | 2 (8.33%) |
| Company Name | Oncimmune Holdings Plc |
| Address |
medicity – d6 building nottingham NG90 6BH |
| Website | https://www.oncimmune.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
